Acute peripheral catecholaminergic changes in rat after MPTP and MPP+ treatment.
The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its main metabolite 1-methyl-4-phenylpyridinium ion (MPP+) on the peripheral catecholaminergic system of the rat were investigated. MPTP and MPP+ injections (20 mg/kg i.p.) caused a marked acute depletion of heart noradrenaline, up to 75% twelve hours after the administration, and a decrease of adrenal gland adrenaline. The time-course of the effect of MPTP and MPP+ is reported, together with a decrease in the tyrosine hydroxylase activity after MPTP treatment, more evident in the adrenal glands. Pargyline (50 mg/kg i.p.) is not able to prevent such a neurotoxic peripheral effect.
Ambrosio
S
S
Departamento de Ciencias Fisiológicas, Humanas y de la Nutrición, Facultad de Medicina, Barcelona, Spain.
Mahy
N
N
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015655:1-Methyl-4-phenylpyridinium; D000313:Adrenal Medulla / Q000032:analysis / Q000187:drug effects*; D000818:Animals; D006321:Heart / Q000187:drug effects*; D008297:Male; D009206:Myocardium / Q000032:analysis*; D009638:Norepinephrine / Q000032:analysis*; D010293:Pargyline / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology / Q000633:toxicity*; D011726:Pyridinium Compounds / Q000494:pharmacology / Q000633:toxicity*; D051381:Rats; D011919:Rats, Inbred Strains; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis
D011725:Pyridines; D011726:Pyridinium Compounds; D010293:Pargyline; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D014446:Tyrosine 3-Monooxygenase; D015655:1-Methyl-4-phenylpyridinium; D009638:Norepinephrine